Savonix, Bayer to validate multivitamin supplement Berocca effects in Malaysia

KUALA LUMPUR, Sept 18 -- Savonix and Bayer’s Consumer Health Division have announced a partnership agreement to validate the effects of Bayer’s multivitamin supplement Berocca in the Malaysian market.

In this study, a Savonix digital cognitive assessment, which takes around 10 minutes to complete, will be administered to 200 university students between the ages of 18 to 25, including both Berocca and non-Berocca users.

The assessment platform is a valid and reliable method to assess Berocca’s effectiveness on brain performance in real world settings and help consumers understand their cognitive health.

In addition, the platform delivers a set of digitised neurocognitive tests via Android and iOS mobile operating systems, supported by a web-based clinical data dashboard with integrated clinical decision support and treatment planning guidance.

Berocca is a multivitamin effervescent tablet that contains all eight B vitamins, helping to sustain energy for mental and physical performance.

Savonix is a global leader in digital tests for cognitive health, empowering healthcare providers, payers and researchers to evaluate and leverage results to improve health and treatment outcomes. More details at https://www.savonix.com/

-- BERNAMA